跳至主要内容
临床试验/IRCT20190619043942N1
IRCT20190619043942N1已完成4 期

Impact of Octreotide on Renal Function of Patients after Liver Transplantation; A Randomized, Double-Blind, Placebo-Controlled Trial

Shiraz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • 1.Age between 18 and 60 years 2.Cirrhosis of the liver defined by clinical, biochemical or histological That, properly informed, give their consent to participate in the study and undergo tests and examinations that entails Women of childbearing potential: pregnancy test negative serum or urine, and acceptance of use of adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last dose

排除标准

  • 1.Pregnant women, nursing mothers, or those who intend to become pregnant during the study period 2.Systolic blood pressure = 150 mmHg and / or diastolic blood pressure = 90 mmHg 3.Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunts 4.Simultaneous Liver, Kidney Transplant 5.Cardiac or respiratory failure 6.Positive for human immunodeficiency virus 7.Urinary retention 8.Ischemic heart disease or peripheral vascular disease9.Narrow Angle Glaucoma 10.Cerebrovascular occlusions 11.Aortic Aneurysm 12.Thyrotoxicosis 13.Pheochromocytoma 14.Diabetes Melitus 15.History of Hemodialysis prior to Liver Transplant 16.PreTransplant Cr more than 2.5mg/dl

研究者

相似试验